Amid tariff uncertainty and its possibly adverse implications for inflation and corporate earnings, the major US equity indices, after massive rallies post-April lows, are witnessing sellers come out at/near resistance.
Separately, Regeneron on Monday also announced positive interim data from its ongoing Phase 2 trial investigating novel combinations of semaglutide and Trevogrumab with or without garetosmab for the treatment of obesity.
